DGDA (Bangladesh)

The Bangladesh Directorate General of Drug Administration (DGDA — ঔষধ প্রশাসন অধিদপ্তর) operating under the Ministry of Health and Family Welfare (MoHFW) is the People's Republic of Bangladesh's national regulatory authority for human + veterinary medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + traditional + complementary medicines (Unani + Ayurvedic + Homeopathic + Herbal) + pharmacy practice + controlled substances + clinical trials. The DGDA operates under the Drugs and Cosmetics Act 2023 (the foundational modernised pharmaceutical law) + Drugs (Control) Rules + Bangladesh Pharmacy Council Act 2013 + Narcotic Substances Control Act 2018 + DGDA Director General Orders + DGDA Office Circulars + DGDA Guidelines.

DGDA organisational structure includes:

• Minister of Health and Family Welfare — political head; appointed by the Prime Minister.
• Secretary, Health Services Division (MoHFW) — administrative head.
• Director General, DGDA — DGDA chief executive.
• Directors (Administration, Drug Registration, Drug Control, Drug Testing Laboratory) — operational directors.
• Drug Registration Branch — drug + biological + vaccine + generic registration.
• Drug Control Branch — GMP + GDP + GPP inspections of Bangladeshi + foreign manufacturing facilities.
• Pharmacy Practice + Licensing Branch — pharmacy + pharmaceutical-establishment licensing in coordination with Bangladesh Pharmacy Council.
• Medical Devices + Cosmetics Branch — medical-device + IVD + cosmetic registration.
• Controlled Substances + Narcotics Branch — narcotics + psychotropics framework coordination with Department of Narcotics Control + Bangladesh Customs.
• Pharmacovigilance Centre — WHO PIDM affiliated national pharmacovigilance hub.
• Clinical Trials + Bioequivalence Branch — CTA + Ethics Committee + IRB coordination.
• Drug Testing Laboratory (Mohakhali, Dhaka + Chattogram regional lab) — pharmaceutical + biological + diagnostic testing capacity pursuing ISO/IEC 17025 + WHO PQ-Lab status.
• International Affairs Branch — WHO + SAARC + OIC + bilateral coordination.
• 8 Divisional Drug Superintendent Offices + 64 District Drug Superintendent Offices — operational structure providing substantial national coverage including Mobile Court enforcement.
• Bangladesh Pharmacy Council (BPC) — statutory body under Pharmacy Council Act 2013 regulating pharmacist licensure (A/B/C grade pharmacists) + pharmacy education.

Bangladesh's distinctive pharmaceutical-self-sufficiency + export-success operational context: Bangladesh operates one of the world's most successful pharmaceutical-self-sufficiency + export-success models — domestic manufacturers cover ~98% of domestic-volume consumption + Bangladesh exports pharmaceuticals to ~150+ countries reaching ~USD 200+ million annual export value. This success is substantially enabled by the WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) providing substantial generic-manufacturing operational space allowing Bangladeshi manufacturers to manufacture + export generic versions of patented medicines before patent expiry in non-LDC jurisdictions. Bangladesh has ~300+ Bangladeshi-domestic manufacturers including Beximco Pharmaceuticals + Square Pharmaceuticals + Incepta Pharmaceuticals + Renata + ACI Pharmaceuticals + Eskayef + Healthcare Pharmaceuticals + Drug International + Opsonin + Pharmasia + General Pharmaceuticals + Aristopharma + Sanofi Bangladesh + Novartis Bangladesh. Bangladesh's pharmaceutical-export markets include substantial Asian + African + Latin American + European + North American jurisdictions with substantial UK + Australian + Canadian + EU MS + US FDA + WHO PQ + UN-agency procurement engagement.

DGDA is distinct from + complementary to: the Bangladesh Pharmacy Council (BPC — statutory body regulating pharmacist licensure + pharmacy education); the Bangladesh Medical and Dental Council (BMDC — physician + dental licensing); the Bangladesh Association of Pharmaceutical Industries (BAPI — representing manufacturers); Department of Narcotics Control (substantial narcotics enforcement); Bangladesh Customs (import-export control); 8 Divisional + 64 District Drug Superintendent offices (provincial drug inspection + enforcement including Mobile Court enforcement); academic-medical-centre clinical-research hubs (Dhaka University + Bangabandhu Sheikh Mujib Medical University + ICDDR,B + Dhaka Medical College + Chattogram Medical College). Bangladesh's pharmaceutical environment is uniquely characterised by: substantial domestic pharmaceutical-manufacturing capacity covering ~98% of domestic-volume consumption; substantial export-industry to ~150+ countries; WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) operational space; substantial halal-pharmaceutical certification capacity; Bangla + English overlay labelling; substantial Climate Zone IVa Indo-Gangetic Plain + IVb monsoon-affected stability requirements; substantial Mobile Court enforcement of counterfeit + substandard medicine quality risks.

DGDA is a WHO PIDM Member + WHO SEARO observer + SAARC Member State + OIC Member State + WHO PQ programme participant + ICH Observer + IGBA Member State + maintains substantial bilateral cooperation with Indian CDSCO + Pakistani DRAP + Sri Lankan NMRA + Nepalese DDA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH + Myanmar FDA + Chinese NMPA + UK MHRA + EU EMA + US FDA + Japanese PMDA + Korean MFDS + Turkish TİTCK + Iranian IFDA + GCC GHC + EAC ECSA-HC.

Bangladeshi pharmaceutical regulation operates under a layered framework of Acts + Rules + DGDA Director General Orders + DGDA Office Circulars + DGDA Guidelines — substantively incorporating WHO + ICH + PIC/S GMP + EU GMP + WHO TRS Annex elements:

• Drugs and Cosmetics Act 2023 — foundational modernised pharmaceutical law (replacing Drugs Act 1940 + Drugs Control Ordinance 1982).
• Drugs Control Ordinance 1982 (transitional provisions still in force) — historical pharmaceutical control framework.
• Drugs (Control) Rules — operational rules under DCO 1982 + DCA 2023.
• Bangladesh Pharmacy Council Act 2013 — pharmacist licensure framework (A/B/C grade pharmacists).
• Narcotic Substances Control Act 2018 — narcotics + psychotropics framework coordinated with Department of Narcotics Control.
• Bangladesh National Drug Policy (most recently 2016) — strategic pharmaceutical policy framework + Essential Drugs List + National Formulary.
• DGDA Drug Registration Guidelines — substantive drug registration framework.
• DGDA Medical Device Guidelines — substantively incorporating WHO + IMDRF + EU MDR + IVDR elements.
• DGDA Cosmetics Guidelines — substantively incorporating EU Cosmetics Regulation elements.
• DGDA GMP Guide — substantively aligned with WHO TRS 986 Annex 2 + PIC/S GMP + EU GMP elements.
• DGDA GDP Guide — substantively aligned with WHO GDP + EU GDP elements.
• DGDA GCP Guide — substantively aligned with ICH E6(R2) + WHO GCP guidance.
• DGDA GVP Guide — substantively aligned with WHO PV guidance + ICH E2 + EU GVP elements.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + International Pharmacopoeia + Indian Pharmacopoeia + Bangladesh National Formulary.
• Bangladesh National Essential Medicines List + Bangladesh National Formulary — substantively aligned with WHO Essential Medicines List.
• WHO TRIPS LDC Pharmaceutical Patent Waiver Operational Framework — substantial generic-manufacturing operational space (extended through 2034) allowing Bangladeshi manufacturers to manufacture + export generic versions of patented medicines before patent expiry in non-LDC jurisdictions.
• Halal Pharmaceutical Certification Framework — substantial halal-pharmaceutical certification capacity via Islamic Foundation Bangladesh + Bangladesh Standards and Testing Institution (BSTI).
• Variations + Registration Renewal framework.
• Mobile Court Enforcement Framework — substantial Mobile Court enforcement under Mobile Court Act 2009 + DGDA enforcement teams for counterfeit + substandard medicine surveillance.

DGDA operates the Drug Testing Laboratory (DTL) Mohakhali Dhaka + Chattogram regional laboratory — substantial pharmaceutical + biological + diagnostic testing capacity pursuing ISO/IEC 17025 + WHO PQ-Lab status via WHO + bilateral-donor capacity expansion. The DGDA Drug Control Branch conducts substantial GMP + GDP + GPP inspections of ~300+ Bangladeshi-domestic manufacturing facilities + foreign manufacturing facilities for imported drug registration.

• ISO/IEC 17025 — DTL pursuing ISO/IEC 17025 accreditation via WHO + bilateral-donor capacity expansion.
• WHO PQ-Lab — DTL pursuing WHO PQ-Lab status via WHO + bilateral-donor capacity expansion.
• Vaccine cold-chain QC — substantial cold-chain capacity for Bangladesh Expanded Programme on Immunization (EPI) via WHO + UNICEF + Gavi-supported infrastructure.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + substantial post-market surveillance + Mobile Court enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Counterfeit-medicine forensics — substantial forensic analytical support for DGDA Mobile Court enforcement + Bangladesh Customs + Department of Narcotics Control + WHO Global Surveillance & Monitoring System contributions.
• Substantial export-industry QC support — DTL supports substantial Bangladeshi pharmaceutical-export industry quality assurance reaching ~150+ countries.
• GMP Inspectorate — substantial DGDA Drug Control Branch capability for Bangladeshi-domestic manufacturing facility GMP inspections including ~300+ manufacturers + foreign manufacturing facility inspections for imported drug registration.
• Bangladeshi domestic manufacturer support — supports substantial Bangladeshi-domestic pharmaceutical-manufacturing industry covering ~98% of domestic-volume consumption + substantial export-industry to ~150+ countries notably Beximco Pharmaceuticals + Square Pharmaceuticals + Incepta Pharmaceuticals + Renata + ACI Pharmaceuticals + Eskayef + Healthcare Pharmaceuticals + Drug International + Opsonin + Pharmasia + General Pharmaceuticals + Aristopharma + Sanofi Bangladesh + Novartis Bangladesh.

DGDA medical-device + IVD regulation operates under DGDA Medical Device Guidelines substantively incorporating WHO + IMDRF + EU MDR + IVDR + GHTF elements. Bangladesh has emerging domestic medical-device-manufacturing capacity with substantial Indian + Chinese + Pakistani + Turkish + European + US medical-device-import dependency for advanced devices.

• Risk-based Classification — substantively aligned with WHO + IMDRF + EU MDR + IVDR + GHTF model.
• Bangladeshi Authorised Representative — Bangladesh-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + DGDA regulatory interface.
• ISO 13485:2016 — recognised by DGDA as QMS evidence framework.
• Reliance pathways — DGDA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + WHO PQ + Indian CDSCO + Pakistani DRAP approval evidence as supporting evidence.
• Post-market vigilance — DGDA operates medical-device adverse-event reporting; reporting timelines substantively aligned with WHO + IMDRF Adverse Event Reporting Codes.
• IVD Reactivigilance — DGDA operates IVD reactivigilance reflecting Bangladesh's substantial clinical-laboratory infrastructure + ICDDR,B research-laboratory capacity.
• Cosmetic Notification — cosmetics require DGDA Cosmetic Notification + Bangla/English labelling; INCI-aligned ingredient listing + safety substantiation.
• Traditional + Complementary Medicines — distinctive Bangladeshi-traditional Unani + Ayurvedic + Homeopathic + Herbal medicine framework recognising substantial South Asian + Bengali traditional-medicine heritage including substantial Hakim + Vaidya + Homeopath + Kabiraj practitioner cadre.
• Halal Cosmetic + Pharmaceutical Certification — substantial Halal Cosmetic + Pharmaceutical Certification capacity via Islamic Foundation Bangladesh + BSTI providing substantial OIC + GCC + South-East Asian halal-cosmetic + halal-pharmaceutical export-market access.

DGDA operates the Bangladesh Pharmacovigilance Centre coordinated by DGDA's Pharmacovigilance Branch. Bangladesh is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Bangladesh Pharmacovigilance Centre coordinates with 8 Divisional + 64 District Drug Superintendent offices + healthcare-delivery facilities + Marketing Authorisation Holders + ICDDR,B substantial research-pharmacovigilance capacity. Bangladeshi pharmacovigilance is uniquely shaped by substantial vaccine surveillance commitments (Bangladesh Expanded Programme on Immunization + Gavi-supported campaigns) + substantial counterfeit-medicine quality-risk monitoring + substantial Mobile Court enforcement + substantial export-industry post-market surveillance reaching ~150+ countries.

• Bangladesh Pharmacovigilance Centre — coordinated by DGDA Pharmacovigilance Branch.
• WHO PIDM Member — Bangladesh contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Bangladesh PV Network — coordinated national network with effector centres in 8 Divisional + 64 District Drug Superintendent offices + healthcare-delivery facilities + Marketing Authorisation Holders + ICDDR,B.
• ADR Reporting — DGDA operates ADR reporting via Bangladesh Pharmacovigilance Centre; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DGDA accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with ICH E2 + WHO PV guidance.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
• Risk Management Plans (RMP) — DGDA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — Bangladesh Pharmacovigilance Centre operates active-surveillance programmes for COVID-19 vaccines + childhood immunisation + high-risk products.
• AEFI Surveillance — Bangladeshi vaccine adverse-event surveillance aligned with WHO methodology; substantial to Bangladesh Expanded Programme on Immunization + UNICEF + Gavi-supported immunisation campaigns.
• Matériovigilance + Cosmétovigilance — DGDA operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — substantial DGDA Mobile Court enforcement role for counterfeit + substandard medicine quality risks including ~300+ domestic manufacturer surveillance + substantial cross-border Indian + Pakistani + Chinese pharmaceutical-trade quality monitoring.
• Export-Industry Post-Market Surveillance — substantial post-market surveillance support for Bangladeshi pharmaceutical-export industry reaching ~150+ countries + substantial WHO Global Surveillance & Monitoring System contributions.

• WHO PIDM Member — Bangladesh contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• WHO PQ Programme Participant + Substantial Bangladeshi-Manufacturer WHO PQ Programme Participation — substantial Bangladeshi manufacturer WHO PQ-listed generics + vaccines + biologicals via Beximco + Square + Incepta + Renata + ACI + Eskayef + Healthcare + Drug International + Opsonin + Aristopharma + Sanofi Bangladesh + Novartis Bangladesh.
• WHO SEARO observer — substantial WHO South-East Asia Regional Office cooperation reflecting Bangladesh's South Asian regional position.
• SAARC Member State — South Asian Association for Regional Cooperation (8 Member States — Afghanistan + Bangladesh + Bhutan + India + Maldives + Nepal + Pakistan + Sri Lanka); substantial SAARC pharmaceutical regulatory cooperation including Bangladesh SAARC Secretariat host country.
• OIC Member State — Organisation of Islamic Cooperation Member State substantial pharmaceutical cooperation + halal-pharmaceutical certification cooperation.
• ICH Observer — substantial ICH guideline implementation in Bangladeshi regulatory practice.
• IGBA Member State — International Generic and Biosimilar medicines Association substantial Bangladeshi-manufacturer generic-industry representation reflecting substantial ~98% domestic-volume self-sufficiency + ~USD 200+ million annual export.
• WTO TRIPS LDC Pharmaceutical Patent Waiver Beneficiary — substantial WTO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) providing substantial generic-manufacturing operational space.
• Indian CDSCO Bilateral — substantial South Asian + SAARC peer + cross-border pharmaceutical-trade + harmonisation cooperation + substantial Bangladeshi pharmaceutical-export to India.
• Pakistani DRAP Bilateral — substantial South Asian + SAARC peer + halal-pharmaceutical cooperation + substantial Bangladeshi pharmaceutical-export to Pakistan.
• Sri Lankan NMRA Bilateral — substantial South Asian + SAARC + Indian-Ocean regional peer + substantial Bangladeshi pharmaceutical-export to Sri Lanka.
• Nepalese DDA + Bhutanese DRA + Maldivian MFDA Bilateral — substantial SAARC peer cooperation + substantial Bangladeshi pharmaceutical-export.
• Afghanistan MoPH Bilateral — substantial SAARC peer + substantial Bangladeshi pharmaceutical-export to Afghanistan via humanitarian channels.
• Myanmar FDA Bilateral — substantial cross-border + ASEAN peer cooperation + substantial Bangladeshi pharmaceutical-export to Myanmar.
• Chinese NMPA Bilateral — Belt and Road operational engagement + substantial Chinese API-import dependency + bilateral pharmaceutical-trade cooperation.
• UK MHRA + EU EMA + US FDA Bilateral — substantial historical Commonwealth + substantial export-market regulator cooperation.
• Japanese PMDA + Korean MFDS + Turkish TİTCK + Iranian IFDA + GCC GHC + EAC ECSA-HC Bilateral — substantial export-market regulator cooperation reflecting Bangladeshi pharmaceutical-export industry to ~150+ countries.
• ICDDR,B — International Centre for Diarrhoeal Disease Research, Bangladesh — substantial global research institution headquartered in Dhaka providing substantial pharmaceutical + vaccine + clinical research capacity globally.

• Drugs and Cosmetics Act 2023 transitional provisions under-planned — most operationally significant recent DGDA achievement; substantial transitional provisions between DCA 2023 + legacy DCO 1982 + Drugs (Control) Rules framework frequently under-planned by foreign manufacturers.
• WHO TRIPS LDC pharmaceutical-patent waiver operational space under-leveraged — most operationally significant feature of Bangladeshi pharmaceutical market access; substantial WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) generic-manufacturing operational space frequently under-leveraged by foreign-licensor + Bangladeshi-manufacturer joint-venture + technology-transfer opportunities.
• Bangladeshi Authorised Representative not properly designated — application rejected at DGDA intake or post-approval compliance failure; Bangladeshi Authorised Representative must be Bangladesh-resident legal entity with appropriate licensure.
• Bangla + English labelling deficiencies — Bangla + English required; many applicants provide insufficient Bangla language patient leaflet content.
• DGDA GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Bangladeshi-specific DGDA GMP clarifications.
• Bangladeshi climate-zone stability data missing — Bangladesh spans Climate Zone IVa Indo-Gangetic Plain + IVb monsoon-affected coastal; requires substantial zonal-specific stability data including monsoon-humidity considerations.
• WHO PQ programme reliance under-utilised — substantial WHO PQ-approved-product reliance pathway substantially accelerating DGDA review frequently under-utilised.
• SRA reliance under-utilised — substantial EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS reliance pathway frequently under-utilised.
• SAARC peer reliance under-utilised — substantial Indian CDSCO + Pakistani DRAP + Sri Lankan NMRA peer reliance pathway reflecting South Asian + SAARC operational reality frequently under-utilised.
• Halal-pharmaceutical certification pathway under-utilised — substantial halal-pharmaceutical certification capacity via Islamic Foundation Bangladesh + BSTI providing substantial OIC + GCC + South-East Asian halal-pharmaceutical export-market access frequently under-utilised.
• Bioequivalence centres + biowaiver — DGDA BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• Mobile Court enforcement under-anticipated — substantial DGDA Mobile Court enforcement under Mobile Court Act 2009 + DGDA enforcement teams for counterfeit + substandard medicine surveillance frequently under-anticipated.
• Substantial Bangladeshi-domestic manufacturer joint-venture not leveraged — substantial Bangladeshi-domestic pharmaceutical-manufacturing capacity including ~300+ manufacturers covering ~98% of domestic-volume consumption + substantial export-industry to ~150+ countries substantially under-leveraged for foreign-manufacturer technology-transfer + joint-venture opportunities particularly under WHO TRIPS LDC pharmaceutical-patent waiver operational space.
• Substantial Bangladeshi academic-medical-centre clinical-research capacity not leveraged — substantial Dhaka University + Bangabandhu Sheikh Mujib Medical University + ICDDR,B + Dhaka Medical College + Chattogram Medical College + 173-million-population clinical-research capacity substantially under-leveraged.
• ICDDR,B research-pharmacovigilance capacity not leveraged — substantial International Centre for Diarrhoeal Disease Research, Bangladesh global-research-institution capacity substantially under-leveraged for substantial pharmaceutical + vaccine + clinical research opportunities.
• Substantial export-industry compliance not leveraged — substantial Bangladeshi pharmaceutical-export industry reaching ~150+ countries + substantial UK + Australian + Canadian + EU MS + US FDA + WHO PQ + UN-agency procurement engagement substantially under-leveraged for substantial export-market regulator compliance + harmonisation opportunities.
• Variations strategy not planned — variations procedure with Bangladeshi-specific timelines + fee structure.
• Registration renewal timing missed — registration renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.
• SAARC + OIC + Indian-Ocean regional bridging not leveraged — substantial SAARC + OIC + Indian-Ocean regional regulatory cooperation + harmonisation opportunities substantially under-leveraged.

V5 Ultimate provides the operational infrastructure Bangladeshi + foreign-supplier sites need for the Drugs and Cosmetics Act 2023 + Drugs (Control) Rules + DGDA Drug Registration + DGDA GMP + DGDA Medical Device Guidelines + DGDA Cosmetics Guidelines + WHO PQ programme participation + WHO TRIPS LDC pharmaceutical-patent waiver operational space + SAARC + OIC + Indian-Ocean regional cooperation + Bangladesh Pharmacovigilance Centre + substantial export-industry compliance reaching ~150+ countries.

• DGDA GMP control framework — WHO TRS 986 Annex 2 + PIC/S + EU GMP elements-aligned controls with ALCOA+ data-integrity + Bangladeshi-specific clarifications + Climate Zone IVa Indo-Gangetic Plain + IVb monsoon-affected stability monitoring.
• DGDA registration dossier packaging — Bangladeshi CTD-aligned dossier structure with Bangladeshi Module 1 specifics + Module 3 stability + Bangla/English patient leaflet + Bangladeshi Authorised Representative declarations + Drugs and Cosmetics Act 2023 framework + substantial EU Module reuse.
• WHO TRIPS LDC pharmaceutical-patent waiver workflow — most operationally significant feature; substantial WHO TRIPS LDC pharmaceutical-patent waiver (extended through 2034) generic-manufacturing operational space packaging including substantial foreign-licensor + Bangladeshi-manufacturer joint-venture + technology-transfer opportunities support.
• Drugs and Cosmetics Act 2023 transitional workflow — substantial transitional provisions between DCA 2023 + legacy DCO 1982 + Drugs (Control) Rules framework packaging.
• WHO PQ programme reliance workflow — substantial WHO PQ-approved-product reliance pathway packaging.
• SRA reliance workflow — DGDA-EMA + DGDA-FDA + DGDA-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging.
• SAARC peer reliance workflow (Indian CDSCO / Pakistani DRAP / Sri Lankan NMRA / Nepalese DDA / Bhutanese DRA / Maldivian MFDA / Afghanistan MoPH) — substantial SAARC peer reliance packaging reflecting Bangladesh SAARC Secretariat host country.
• Halal-pharmaceutical certification workflow — substantial halal-pharmaceutical certification capacity via Islamic Foundation Bangladesh + BSTI packaging providing substantial OIC + GCC + South-East Asian halal-pharmaceutical export-market access.
• Bangladeshi Authorised Representative workflow — foreign-manufacturer Bangladeshi Authorised Representative designation + role-management + Bangladesh-specific post-market surveillance.
• Bangladeshi clinical-trial workflow — DGDA CTA + Dhaka University + Bangabandhu Sheikh Mujib Medical University + ICDDR,B + Dhaka Medical College + Chattogram Medical College Ethics Committee + IRB coordination + Bangladeshi SUSAR reporting via Bangladesh Pharmacovigilance Centre.
• Bangladesh Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Bangladeshi ICSR + Bangladesh PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + traditional-medicine workflow — DGDA frameworks dossier packaging + risk-based classification + ISO 13485 + Bangladeshi Authorised Representative + post-market vigilance + distinctive Bangladeshi-traditional Unani + Ayurvedic + Homeopathic + Herbal traditional-medicine framework.
• Mobile Court enforcement workflow — substantial DGDA Mobile Court enforcement under Mobile Court Act 2009 + DGDA enforcement teams for counterfeit + substandard medicine quality-risk monitoring + WHO Global Surveillance & Monitoring System integration.
• Export-industry compliance workflow — substantial Bangladeshi pharmaceutical-export industry reaching ~150+ countries compliance packaging including substantial UK + Australian + Canadian + EU MS + US FDA + WHO PQ + UN-agency procurement engagement support.
• Bangladeshi-domestic manufacturer support workflow — substantial Bangladeshi-domestic pharmaceutical-manufacturing capacity packaging including technology-transfer + joint-venture opportunities support for ~300+ Bangladeshi-domestic manufacturers covering ~98% of domestic-volume consumption.
• ICDDR,B research-pharmacovigilance integration — substantial International Centre for Diarrhoeal Disease Research, Bangladesh global-research-institution capacity packaging for substantial pharmaceutical + vaccine + clinical research opportunities.
• SAARC + OIC + Indian-Ocean regional bridging — for companies operating across SAARC + OIC + Indian-Ocean regional jurisdictions, V5 surfaces DGDA + India CDSCO + Pakistan DRAP + Sri Lanka NMRA + Nepalese DDA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH + Myanmar FDA + Chinese NMPA + GCC GHC harmonised dossier-element reuse alongside national-specific extensions.